Agios Pharmaceuticals AGIO
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: +$4.75M (9 inflow days, 11 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 37.2% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 12.78% to 10.93% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Morgan Stanley | Public Company | 2026/Q3 | +2,473,333 | 5.7% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +1,782,457 | 3.2% |
| Renaissance Technologies Corp. | Hedge Fund | 2026/Q3 | +505,600 | 0.8% |
| GW&K Investment Management, LLC | Mutual Fund | 2026/Q3 | +189,815 | 2.3% |
| ADAR1 Capital Management, LLC | Hedge Fund | 2026/Q3 | +1,147,381 | 2.2% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +859,521 | 1.8% |
| Lynx1 Capital Management LP | Mutual Fund | 2026/Q3 | +797,369 | 5.7% |
| BlackRock | Mutual Fund | 2026/Q3 | +701,040 | 10.8% |
| AQR Capital Management | Hedge Fund | 2026/Q3 | +640,748 | 1.1% |
| Macquarie Investment Management Business Trust | Mutual Fund | 2026/Q3 | +616,374 | 3.5% |
| Arrowstreet Capital, Limited Partnership | Mutual Fund | 2026/Q3 | +560,069 | 1.4% |
| Defilade Capital Management, L.P. | Hedge Fund | 2026/Q3 | +546,848 | 0.9% |
| Point72 Asset Management, L.P. | Hedge Fund | 2026/Q3 | +506,344 | 0.8% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q3 | +425,836 | 5.2% |
| Qube Research & Technologies Ltd | Mutual Fund | 2026/Q3 | +409,971 | 1.0% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 25 Oct 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Intent to Sell (Form 144) | -7,866 | $37.69 | – |
| 25 Oct 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -7,866 | $37.69 | 54,645 |
| 21 Oct 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Intent to Sell (Form 144) | -500 | $37.52 | – |
| 21 Oct 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -1,989 | $37.53 | 54,645 |
| 20 Oct 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Intent to Sell (Form 144) | -1,489 | $37.53 | – |
| 3 Aug 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Automatic Disposition | -30,000 | $30.48 | 54,645 |
| 7 Jul 2026 | Jay Backstrom | Independent Director | Other Acquisition | +1,447 | – | 1,447 |
| 30 Jun 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -4,007 | $37.56 | 84,645 |
| 30 Jun 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Retained | +4,368 | – | 84,645 |
| 17 Jun 2026 | Jacqualyn Fouse | Chair of the Board of Directors | Other Derivative Acquisition | +2,927 | – | 2,927 |
| 17 Jun 2026 | Jacqualyn Fouse | Chair of the Board of Directors | Other Derivative Acquisition | +14,950 | $34.16 | 14,950 |
| 17 Jun 2026 | Jacqualyn Fouse | Chair of the Board of Directors | Derivative Exercise and Retained | +2,816 | – | 154,156 |
| 17 Jun 2026 | Jeffrey Capello | Independent Director | Other Derivative Acquisition | +2,927 | – | 2,927 |
| 17 Jun 2026 | Jeffrey Capello | Independent Director | Other Derivative Acquisition | +14,950 | $34.16 | 14,950 |
| 17 Jun 2026 | Jeffrey Capello | Independent Director | Derivative Exercise and Retained | +2,816 | – | 10,865 |
| 17 Jun 2026 | Kaye Foster-Cheek | Lead Independent Director | Other Derivative Acquisition | +2,927 | – | 2,927 |
| 17 Jun 2026 | Kaye Foster-Cheek | Lead Independent Director | Other Derivative Acquisition | +14,950 | $34.16 | 14,950 |
| 17 Jun 2026 | Kaye Foster-Cheek | Lead Independent Director | Derivative Exercise and Retained | +2,816 | – | 12,484 |
| 17 Jun 2026 | Jay Backstrom | Independent Director | Other Derivative Acquisition | +2,927 | – | 2,927 |
| 17 Jun 2026 | Jay Backstrom | Independent Director | Other Derivative Acquisition | +14,950 | $34.16 | 14,950 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 6,524,140 | 10.9% | 5.2 |
| 15 Oct 2026 | 6,894,856 | 11.5% | 5.6 |
| 30 Sep 2026 | 7,016,166 | 11.8% | 6.4 |
| 15 Sep 2026 | 7,557,252 | 12.7% | 9.5 |
| 31 Aug 2026 | 7,535,054 | 12.6% | 8.4 |
| 14 Aug 2026 | 7,629,012 | 12.8% | 7.0 |
No comments yet — be the first to weigh in on AGIO.
Sign in to join the discussion.